ERBB2 and breast carcinoma: Lapatinib as a small molecule inhibitor of HER2, has been developed to expand the options for treating HER‐positive breast cancer.[69] Further, we found that the combined usage of etomoxir (50 μm) and lapatinib significantly decreased the cell viability of BT‐474 cells than that using lapatinib alone (Figure 7L).